IFNs type II (γ), one of the main cytokines released by effector CD8+ T cells, emerges as a crucial component of the tumor immunosurveillance system, which determines the outcome of checkpoint blockade treatment (Dighe et al., 1994; Kaplan et al., 1998; Jorgovanovic et al., 2020). This evidence concerns the gene CD8A and neoplasm.